{"id":"https://openalex.org/W4361895406","doi":"https://doi.org/10.1158/0008-5472.22390958.v1","title":"Supplementary Figure 4 from Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis","display_name":"Supplementary Figure 4 from Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis","publication_year":2023,"publication_date":"2023-03-30","ids":{"openalex":"https://openalex.org/W4361895406","doi":"https://doi.org/10.1158/0008-5472.22390958.v1"},"language":"en","primary_location":{"id":"doi:10.1158/0008-5472.22390958.v1","doi":"https://doi.org/10.1158/0008-5472.22390958.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/0008-5472.22390958.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_4_from_Human_CD59_Inhibitor_Sensitizes_Rituximab-Resistant_Lymphoma_Cells_to_Complement-Mediated_Cytolysis/22390958/1/files/39836489.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_4_from_Human_CD59_Inhibitor_Sensitizes_Rituximab-Resistant_Lymphoma_Cells_to_Complement-Mediated_Cytolysis/22390958/1/files/39836489.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101738196","display_name":"Weiguo Hu","orcid":"https://orcid.org/0000-0003-2156-6233","observed_orcids":["https://orcid.org/0000-0003-2156-6233"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Weiguo Hu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110741632","display_name":"Xiaowen Ge","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xiaowen Ge","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112657990","display_name":"Tao You","orcid":"https://orcid.org/0000-0003-2381-7382","observed_orcids":["https://orcid.org/0000-0003-2381-7382"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tao You","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100385908","display_name":"Ting Xu","orcid":"https://orcid.org/0000-0003-2578-6532","observed_orcids":["https://orcid.org/0000-0003-2578-6532"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ting Xu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100709962","display_name":"Jinyan Zhang","orcid":"https://orcid.org/0000-0003-0267-5397","observed_orcids":["https://orcid.org/0000-0003-0267-5397"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jinyan Zhang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102051693","display_name":"Gongxiong Wu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gongxiong Wu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101460868","display_name":"Zhihai Peng","orcid":"https://orcid.org/0000-0002-0968-9356","observed_orcids":["https://orcid.org/0000-0002-0968-9356"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zhihai Peng","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113917509","display_name":"Michael Chorev","orcid":"https://orcid.org/0000-0003-3533-2913","observed_orcids":["https://orcid.org/0000-0003-3533-2913"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael Chorev","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020661635","display_name":"Bertal Huseyin Aktas","orcid":"https://orcid.org/0000-0001-7829-4553","observed_orcids":["https://orcid.org/0000-0001-7829-4553"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bertal H. Aktas","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086918952","display_name":"Jos\u00e9 A. Halperin","orcid":"https://orcid.org/0000-0003-4749-5285","observed_orcids":["https://orcid.org/0000-0003-4749-5285"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jose A. Halperin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016570475","display_name":"Jennifer R. Brown","orcid":"https://orcid.org/0000-0003-2040-4961","observed_orcids":["https://orcid.org/0000-0003-2040-4961"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jennifer R. Brown","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5002075826","display_name":"Xuebin Qin","orcid":"https://orcid.org/0000-0001-9875-983X","observed_orcids":["https://orcid.org/0000-0001-9875-983X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xuebin Qin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10993","display_name":"Complement system in diseases","score":0.98580002784729,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10993","display_name":"Complement system in diseases","score":0.98580002784729,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.010300000198185444,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rituximab-resistance","display_name":"rituximab resistance","score":0.9900000095367432},{"id":"https://openalex.org/keywords/lymphoma","display_name":"lymphoma","score":0.7269999980926514},{"id":"https://openalex.org/keywords/complement-mediated-cell-lysis","display_name":"complement-mediated lysis","score":0.9559999704360962},{"id":"https://openalex.org/keywords/complement-system","display_name":"complement system","score":0.5600000023841858},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.4690000116825104}],"concepts":[{"id":"https://openalex.org/C73588182","wikidata":"https://www.wikidata.org/wiki/Q2663023","display_name":"Cytolysis","level":4,"score":0.7864941358566284},{"id":"https://openalex.org/C184404459","wikidata":"https://www.wikidata.org/wiki/Q5009828","display_name":"CD59","level":4,"score":0.6399542689323425},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.585551381111145},{"id":"https://openalex.org/C112313634","wikidata":"https://www.wikidata.org/wiki/Q7886648","display_name":"Complement (music)","level":5,"score":0.5295358896255493},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.4636235535144806},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4200159013271332},{"id":"https://openalex.org/C2777726029","wikidata":"https://www.wikidata.org/wiki/Q21114926","display_name":"Complement-dependent cytotoxicity","level":5,"score":0.4169881343841553},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3482833504676819},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3466287851333618},{"id":"https://openalex.org/C111684460","wikidata":"https://www.wikidata.org/wiki/Q334848","display_name":"Complement system","level":3,"score":0.338714063167572},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.29559043049812317},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.26327741146087646},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.15511399507522583},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.11819171905517578},{"id":"https://openalex.org/C40677261","wikidata":"https://www.wikidata.org/wiki/Q21418091","display_name":"Antibody-dependent cell-mediated cytotoxicity","level":4,"score":0.08162793517112732},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.07259154319763184},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.05954501032829285},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.05223402380943298},{"id":"https://openalex.org/C127716648","wikidata":"https://www.wikidata.org/wiki/Q104053","display_name":"Phenotype","level":3,"score":0.045400381088256836},{"id":"https://openalex.org/C188082640","wikidata":"https://www.wikidata.org/wiki/Q1780899","display_name":"Complementation","level":4,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/0008-5472.22390958.v1","doi":"https://doi.org/10.1158/0008-5472.22390958.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/0008-5472.22390958.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_4_from_Human_CD59_Inhibitor_Sensitizes_Rituximab-Resistant_Lymphoma_Cells_to_Complement-Mediated_Cytolysis/22390958/1/files/39836489.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22390958","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Figure_4_from_Human_CD59_Inhibitor_Sensitizes_Rituximab-Resistant_Lymphoma_Cells_to_Complement-Mediated_Cytolysis/22390958","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/0008-5472.22390958.v1","doi":"https://doi.org/10.1158/0008-5472.22390958.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/0008-5472.22390958.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_4_from_Human_CD59_Inhibitor_Sensitizes_Rituximab-Resistant_Lymphoma_Cells_to_Complement-Mediated_Cytolysis/22390958/1/files/39836489.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8560000061988831}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4361895406.pdf","grobid_xml":"https://content.openalex.org/works/W4361895406.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2130867811","https://openalex.org/W4392725819","https://openalex.org/W2062943168","https://openalex.org/W2153255423","https://openalex.org/W4361944094","https://openalex.org/W2032454178","https://openalex.org/W33733012","https://openalex.org/W2065316818","https://openalex.org/W2039226259","https://openalex.org/W2069524809"],"abstract_inverted_index":{"Supplementary":[0],"Figure":[1],"4":[2],"from":[3],"Human":[4],"CD59":[5],"Inhibitor":[6],"Sensitizes":[7],"Rituximab-Resistant":[8],"Lymphoma":[9],"Cells":[10],"to":[11],"Complement-Mediated":[12],"Cytolysis":[13]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2023-04-05T00:00:00"}